FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
GAITHERSBURG, Md., March 16, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its 2016 fourth quarter and year end financial results after close of market Thursday, March 23, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and recent developments.
Dial-in Information
U.S. Dial-In Number: 844-420-8185
International Dial-In Number: 216-562-0481
Conference ID: 87850606
Replay Dial-In Information
U.S. Dial-In Number: 855-859-2056
International Dial-In Number: 404-537-3406
Conference ID: 87850606
The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the company’s website at http://ir.opgen.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Company Contact: Michael Farmer Director, Marketing (240) 813-1284 [email protected] [email protected] Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-235-3060 [email protected]
